Cardinal Health
CAH
$229.51
+0.46%
Cardinal Health, Inc. is a leading healthcare services company specializing in the distribution of pharmaceuticals and medical-surgical products, operating primarily in the U.S. healthcare supply chain. As one of the 'Big Three' pharmaceutical wholesalers alongside McKesson and Cencora, Cardinal Health commands a dominant position in the highly consolidated U.S. pharmaceutical distribution market, serving pharmacies, hospitals, and healthcare providers. The current investor narrative centers on the company's ability to sustain robust revenue growth driven by pharmaceutical distribution, while managing margin pressures and navigating a complex regulatory environment. Recent attention has been amplified by a strong earnings beat in Q3 FY2026, which was overshadowed by a revenue miss, leading to a sharp stock drop, yet the company raised its full-year profit outlook, signaling confidence in its operational trajectory.…
CAH
Cardinal Health
$229.51
Related headlines
Investment Opinion: Should I buy CAH Today?
Rating: Buy. Cardinal Health's strong revenue growth (11.05% YoY), improving gross margins (4.10% vs 3.68% prior year), and robust free cash flow ($1.68B quarterly) support a bullish thesis. The forward P/E of 16.31x is reasonable relative to expected EPS growth, and the analyst consensus Strong Buy with an average target of $270.94 implies 18% upside. The stock's beta of 0.52 offers lower volatility, appealing to risk-averse investors.
Sign up to view all
CAH 12-Month Price Forecast
The AI assessment leans bullish, driven by strong revenue momentum, improving margins, and a supportive analyst outlook. However, the recent revenue miss and high trailing P/E warrant caution. The stance would upgrade to high confidence if gross margins sustain above 4% and revenue growth remains above 10% in the next two quarters. Conversely, a downgrade to neutral would occur if revenue growth falls below 8% or margins contract, signaling a breakdown in the growth thesis.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Cardinal Health's 12-month outlook, with a consensus price target around $270.94 and implied upside of +18.1% versus the current price.
Average Target
$270.94
0 analysts
Implied Upside
+18.1%
vs. current price
Analyst Count
—
covering this stock
Price Range
$235 - $292
Analyst target range
Cardinal Health is covered by 16 analysts, with a consensus recommendation of 'Strong Buy' (mean rating of 1.5). The average target price is $270.94, implying an upside of approximately 18.0% from the current price of $229.51. The distribution of ratings includes 10 Buy, 5 Overweight, and 1 Neutral, indicating a strongly bullish sentiment among analysts. The target price range spans from a low of $235.00 to a high of $292.00, with the high target suggesting potential for further upside if the company continues to execute on its growth strategy, while the low target still implies a modest 2.4% upside, reflecting a relatively tight range that signals high conviction. Recent institutional ratings have been predominantly positive, with firms like TD Cowen, B of A Securities, and Citigroup maintaining Buy ratings, while JP Morgan remains Neutral, indicating a balanced but optimistic outlook. The wide spread between the low and high targets (57 points) suggests some uncertainty regarding the pace of margin expansion and the impact of regulatory changes, but the overall bullish consensus underscores confidence in Cardinal Health's long-term prospects.
Bulls vs Bears: CAH Investment Factors
Cardinal Health presents a compelling growth story with strong revenue momentum, improving margins, and robust cash generation, supported by a bullish analyst consensus. However, the stock trades at a premium valuation, and the recent revenue miss underscores execution risks. The bull case is currently stronger, driven by raised guidance and margin expansion, but the key tension is whether the company can sustain double-digit revenue growth while expanding margins in a competitive, low-margin industry. If growth decelerates or margins stall, the premium valuation could unwind, making this the pivotal factor for the investment thesis.
Bullish
- Strong Revenue Growth: Q3 FY2026 revenue grew 11.05% YoY to $60.94B, driven by pharmaceutical distribution. This robust growth outpaces the industry and supports the company's scale advantage.
- Raised Full-Year Guidance: Despite a revenue miss, management raised its full-year profit outlook, signaling confidence in operational efficiency and margin expansion. This positive revision underpins the forward P/E of 16.31x.
- Improving Gross Margin: Gross margin improved to 4.10% in Q3 FY2026 from 3.68% a year ago, reflecting better cost management and mix. This trend is critical for a low-margin distribution business.
- Strong Free Cash Flow: Free cash flow reached $1.68B in the latest quarter, yielding ~7.8% on market cap. This cash generation supports dividends and buybacks, enhancing shareholder returns.
Bearish
- Revenue Miss in Q3: Q3 revenue of $60.94B missed Wall Street expectations, causing a sharp stock drop. This highlights potential demand softness or competitive pressures in distribution.
- High Trailing P/E: Trailing P/E of 32.68x is well above the historical average of ~20x, suggesting the market is pricing in optimistic future earnings. Any disappointment could trigger multiple compression.
- Negative Shareholders' Equity: Debt-to-equity of -3.45 reflects negative equity due to buybacks and dividends. This limits financial flexibility and increases vulnerability to rising interest rates.
- Low Net Margin: Net margin of 0.65% is razor-thin, typical of distribution but leaves little room for error. Small cost increases or pricing pressure could disproportionately impact profitability.
CAH Technical Analysis
Cardinal Health's stock has demonstrated a robust long-term uptrend, with a 1-year price change of +51.42%, significantly outperforming the S&P 500's +20.48% over the same period. The current price of $229.51 sits at approximately 88.9% of its 52-week range (between $145.87 low and $258.30 high), indicating the stock is trading near its highs, reflecting strong momentum but also potential overextension. The stock's beta of 0.521 suggests it is less volatile than the broader market, which may appeal to risk-averse investors, but the proximity to the 52-week high warrants caution for potential pullbacks.
Beta
0.52
0.52x market volatility
Max Drawdown
-20.6%
Largest decline past year
52-Week Range
$146-$258
Price range past year
Annual Return
+51.4%
Cumulative gain past year
| Period | CAH Return | S&P 500 |
|---|---|---|
| 1m | +4.1% | +3.6% |
| 3m | +14.4% | +2.7% |
| 6m | +2.3% | +11.4% |
| 1y | +51.4% | +18.7% |
| ytd | +11.6% | +12.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CAH Fundamental Analysis
Cardinal Health's revenue trajectory remains robust, with the most recent quarter (Q3 FY2026) reporting revenue of $60.94 billion, a YoY growth of 11.05%, and a sequential increase from $65.44 billion in Q2 FY2026. Over the past four quarters, revenue has grown from $59.71 billion in Q4 FY2025 to $60.94 billion in Q3 FY2026, indicating a steady growth trend, though the Q2 FY2026 figure was notably higher due to seasonal factors. The pharmaceutical distribution segment, which accounts for the majority of revenue, continues to drive growth, while the medical-surgical segment remains a smaller but stable contributor. The company's profitability metrics show a net income of $399 million in the latest quarter, with a net margin of 0.65%, which is typical for the low-margin distribution industry, but gross margin has improved to 4.10% from 3.68% a year ago, indicating better cost management. Operating margin stands at 0.84%, reflecting the company's ability to maintain profitability despite competitive pressures. Cardinal Health's balance sheet shows a debt-to-equity ratio of -3.45, which is negative due to negative shareholders' equity, a common occurrence in the distribution industry due to share buybacks and dividends. The company generated $1.82 billion in operating cash flow and $1.68 billion in free cash flow in the latest quarter, demonstrating strong cash generation capability, with a free cash flow yield of approximately 7.8% based on the current market cap, which is attractive for income-focused investors.
Quarterly Revenue
$60.9B
2026-03
Revenue YoY Growth
+11.1%
YoY Comparison
Gross Margin
4.1%
Latest Quarter
Free Cash Flow
$4.4B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CAH Overvalued?
Given that Cardinal Health is profitable, the primary valuation metric selected is the trailing P/E ratio, which stands at 32.68x, while the forward P/E is 16.31x. The significant gap between trailing and forward P/E implies the market expects substantial earnings growth in the coming year, likely driven by the company's raised guidance and operational improvements. Compared to the industry average, Cardinal Health's forward P/E of 16.31x is at a premium to the sector's average of approximately 15x, reflecting its strong market position and growth prospects. However, the trailing P/E of 32.68x is higher than the historical average of around 20x, indicating that the stock is trading at a premium to its own historical valuation, which may suggest that the market is pricing in optimistic future earnings growth. The PEG ratio of 2.68x further indicates that the stock is not cheap relative to its growth rate, but the low PS ratio of 0.22x and EV/Sales of 0.23x highlight the company's efficient revenue generation relative to its enterprise value.
PE
32.7x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 13x~42x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
17.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks include a negative shareholders' equity of -3.45 debt-to-equity, which stems from aggressive buybacks and dividends, leaving the balance sheet with limited equity cushion. This could constrain borrowing capacity during downturns. The low net margin of 0.65% amplifies sensitivity to cost inflation or pricing concessions, as seen in the Q3 revenue miss that triggered a sharp selloff. However, strong free cash flow of $1.68B in the quarter provides a buffer, but any disruption in cash generation could strain dividend sustainability (payout ratio 28.6%).